Dechert Advises Aquestive Therapeutics on Pricing of US$75 Million Underwritten Public Offering of Common Stock

Dechert recently advised Aquestive Therapeutics, Inc. on the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of US$4.50 per share.

The sale, announced on Tuesday, March 19, is expected to generate gross proceeds of approximately US$75 million for Aquestive, before accounting for underwriting discounts, commissions and other offering expenses.

Aquestive Therapeutics is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. It plans to use the net proceeds from the offering, along with its existing cash and cash equivalents, primarily to further the development and commercialization of its product pipeline. This includes Anaphylm™ (epinephrine) Sublingual Film for treating severe, life-threatening allergic reactions such as anaphylaxis, and Libervant™ (diazepam) Buccal Film for treating seizure clusters in epilepsy patients aged two to five. The funds will also be used for working capital, capital expenditures and other general corporate purposes.

The Dechert team advising Aquestive includes corporate partners David Rosenthal and Anna Tomczyk, associates Austin Day and Dhwani Patel, and counsel Seth Ray.

About Dechert

Dechert is a global law firm that advises asset managers, financial institutions and corporations on issues critical to managing their business and their capital – from high-stakes litigation to complex transactions and regulatory matters. We answer questions that seem unsolvable, develop deal structures that are new to the market and protect clients’ rights in extreme situations. Our 1,000+ lawyers across 21 offices globally focus on the financial services, private equity, private credit, real estate, life sciences and technology sectors.